Eventide Asset Management’s OnKure Therapeutics OKUR Stock Holding History

Eventide Asset Management’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-207,814	Closed	-$15.8M	–	169
2023 Q3	$15.8M	Buy	207,814 +32,814	+19%	+$2.23M	0.28%	99
2023 Q2	$11.5M	Buy	+175,000	New	+$14.1M	0.19%	118

Other funds holding OKUR

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Eventide Asset Management's OKUR Position: Q4 2023 in Review

Eventide Asset Management sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 207,814 shares — an estimated $15.8M sold.

Eventide Asset Management first reported a position in OKUR in Q2 2023 and held it in 2 quarters. The position peaked at $15.8M in Q3 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

Eventide Asset Management reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
Eventide Asset Management sold 207,814 OnKure Therapeutics shares in Q4 2023, an estimated $15.8M.
Eventide Asset Management first reported a position in OnKure Therapeutics in Q2 2023 and held it in 2 quarters.
Eventide Asset Management's OnKure Therapeutics position peaked at $15.8M in Q3 2023.
68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.